{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:46:08Z","timestamp":1769550368988,"version":"3.49.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>During recent years considerable progress has been made in the treatment of multiple myeloma. However, despite the current improvements in the prognosis of this malignancy, it always ends with relapse, and therefore new therapy approaches for destroying resistant cancer cells are needed. Presently, there is great hope being placed in the use of immunotherapy against refractory\/relapsed multiple myeloma which is unresponsive to any other currently known drugs. The most promising one is CAR-T cell therapy which has already shown tremendous success in treating other malignancies such as acute lymphoblastic leukaemia (ALL) and could potentially be administered to multiple myeloma patients. CAR-T cells equipped with receptors against BCMA (B-cell maturation antigen), which is a surface antigen that is highly expressed on malignant cells, are now of great interest in this field with significant results in clinical trials. Furthermore, CAR-T cells with other receptors and combinations of different strategies are being intensively studied. However, even with CAR-T cell therapy, the majority of patients eventually relapse, which is the greatest limitation of this therapy. Serious adverse events such as cytokine release syndrome or neurotoxicity should also be considered as possible side effects of CAR-T cell therapy. Here, we discuss the results of CAR-T cell therapy in the treatment of multiple myeloma, where we describe its main advantages and disadvantages. Additionally, we also describe the current results that have been obtained on using combinations of CAR-T cell therapies with other drugs for the treatment of multiple myeloma.<\/jats:p>","DOI":"10.3389\/fimmu.2021.632937","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T04:31:35Z","timestamp":1614141095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Marcin","family":"Jasi\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz W.","family":"Basak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wies\u0142aw W.","family":"Jedrzejczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Medical Masterclass","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9030601","article-title":"Immunotherapy in Multiple Myeloma","volume":"9","author":"Soekojo","year":"2020","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy108","article-title":"Proteasome inhibitors for multiple myeloma","volume":"48","author":"Okazuka","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.004","article-title":"Hematopoietic Stem Cell Transplantation for Multiple Myeloma","volume":"33","author":"Koniarczyk","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr\u00a0Hematol Malig Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri1729","article-title":"Supernatural T cells: genetic modification of T cells for cancer therapy","volume":"5","author":"Kershaw","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13976","article-title":"The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma","volume":"173","author":"Rotolo","year":"2016","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.024","article-title":"The search for multiple myeloma stem cells: the long and winding road","volume":"16","author":"Basak","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2015.1135185","article-title":"Dose expansion cohorts in Phase I trials","volume":"8","author":"Iasonos","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126660","article-title":"Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129088","article-title":"T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2147\/DDDT.S98053","article-title":"Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma","volume":"11","author":"Friend","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.08.005","article-title":"Cancer stem cells in multiple myeloma","volume":"277","author":"Ghosh","year":"2009","journal-title":"Cancer Lett"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"key":"B62","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126145","article-title":"Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma","volume":"134","author":"Fernandez de Larrea","year":"2019","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119514","article-title":"PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed\/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells","volume":"132","author":"Bernabei","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T04:31:37Z","timestamp":1614141097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2021.632937"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.632937","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"article-number":"632937"}}